4,674 Shares in Icon Plc (ICLR) Purchased by TRUE Private Wealth Advisors
TRUE Private Wealth Advisors acquired a new stake in Icon Plc (NASDAQ:ICLR) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,674 shares of the medical research company’s stock, valued at approximately $524,000.
Other hedge funds have also made changes to their positions in the company. Schwab Charles Investment Management Inc. lifted its stake in Icon by 18.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 21,677 shares of the medical research company’s stock worth $2,432,000 after acquiring an additional 3,386 shares during the last quarter. Bank of Montreal Can lifted its stake in Icon by 22.6% in the fourth quarter. Bank of Montreal Can now owns 167,072 shares of the medical research company’s stock worth $18,738,000 after acquiring an additional 30,754 shares during the last quarter. Summit Creek Advisors LLC lifted its stake in Icon by 21.9% in the fourth quarter. Summit Creek Advisors LLC now owns 142,369 shares of the medical research company’s stock worth $15,967,000 after acquiring an additional 25,533 shares during the last quarter. LVM Capital Management Ltd. MI purchased a new position in Icon in the fourth quarter worth approximately $5,886,000. Finally, Atlantic Trust Group LLC purchased a new position in Icon in the third quarter worth approximately $9,515,000. Hedge funds and other institutional investors own 89.66% of the company’s stock.
A number of research analysts recently issued reports on ICLR shares. Zacks Investment Research downgraded shares of Icon from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Credit Suisse Group reiterated an “outperform” rating and issued a $120.00 price target (up previously from $105.00) on shares of Icon in a research note on Monday, October 16th. KeyCorp reiterated an “overweight” rating and issued a $125.00 price target (up previously from $115.00) on shares of Icon in a research note on Monday, November 13th. They noted that the move was a valuation call. SunTrust Banks reiterated a “buy” rating and issued a $138.00 price target on shares of Icon in a research note on Sunday, October 29th. Finally, ValuEngine upgraded shares of Icon from a “hold” rating to a “buy” rating in a research note on Sunday, December 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $124.91.
Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.03. The business had revenue of $440.30 million during the quarter, compared to the consensus estimate of $438.09 million. Icon had a net margin of 16.37% and a return on equity of 28.42%. The company’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.19 EPS. research analysts expect that Icon Plc will post 5.37 earnings per share for the current fiscal year.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.